Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival

Italiano, A., Toulmonde, M., Cioffi, A., Penel, N., Isambert, N., Bompas, E., Duffaud, F., Patrikidou, A., Lortal, B., Le Cesne, A., Blay, J. Y., Maki, R. G., Schwartz, G. K., Antonescu, C. R., Singer, S., Coindre, J. M., Bui, B. (June 2012) Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol, 23 (6). pp. 1601-7. ISSN 1569-8041 (Electronic)0923-7534 (Linking)

URL: https://www.ncbi.nlm.nih.gov/pubmed/22039081
DOI: 10.1093/annonc/mdr485

Abstract

BACKGROUND: Data regarding the role of systemic therapy in patients with advanced well-differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS) are limited. METHODS: From 2000 to 2010, 208 patients with advanced WDLPS/DDLPS received chemotherapy in 11 participating institutions. Clinical and pathological data were collected by reviewing medical records. RESULTS: Median age was 63 years (range 32-84). Combination chemotherapy was delivered in 85 cases (41%) and single agent in 123 cases (59%), respectively. One hundred and seventy-one patients (82%) received an anthracycline-containing regimen. Using RECIST, objective response was observed in 21 patients (12%), all treated with anthracyclines. Median progression-free survival (PFS) was 4.6 months [95% confidence interval (CI) 3.3-5.9]. On multivariate analysis, age and performance status (PS) were the sole factors significantly associated with poor PFS. Median overall survival (OS) was 15.2 months (95% CI 11.8 -18.7). On multivariate analysis, grade and PS were the sole factors significantly associated with OS. CONCLUSIONS: Chemotherapy was associated with clinical benefit in 46% of patients with advanced WDLPS/DDLPS. OS remains poor, even though visceral metastatic disease is less frequent than in other sarcomas.

Item Type: Paper
Uncontrolled Keywords: Adult Aged Aged, 80 and over Anthracyclines/*therapeutic use Antineoplastic Agents/*therapeutic use Disease-Free Survival Female Humans Kaplan-Meier Estimate Liposarcoma/*drug therapy/mortality/secondary Male Middle Aged Multivariate Analysis Neoplasm Grading Prognosis Proportional Hazards Models Retroperitoneal Neoplasms/*drug therapy/mortality/pathology Retrospective Studies Treatment Outcome
Subjects: diseases & disorders > cancer > drugs and therapies > chemotherapy
diseases & disorders > cancer > drugs and therapies
diseases & disorders > cancer > cancer types > sarcoma
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: June 2012
Date Deposited: 20 Oct 2016 16:52
Last Modified: 20 Oct 2016 16:52
Related URLs:
URI: http://repository.cshl.edu/id/eprint/33738

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving